Our successes

New products and interventions

In 2013/14 researchers reported that their work had led to the development of products or interventions in 12 per cent of awards. This is up from the 10 per cent reported in 2012/13.

We know from principal investigators that there is significant under-reporting of the developments arising from MRC research in this section, and so will be working to improve reporting in this area. 

A targeted effort to capture the details of trials linked to MRC research brought excellent results with more than 200 trials now linked to MRC research.  

In 2013/14 there were 1,019 instances of products and interventions being reported in total, and this has since risen to 1,101.

Products and interventions by type

The therapeutic intervention of drugs was the most common type of product or intervention in development. This was closely followed by non-imaging diagnostic tools. 

The breakdown of products and interventions by type is shown in the tables 1 and 2. 

Table 1: Breakdown of products and interventions by type 

Type of product or intervention

Number of instances

Percentage of total

Diagnostic Tool - imaging

58

6%

Diagnostic Tool - Non-imaging

154

17%

Health and social care services

9

1%

Management of diseases and conditions

43

5%

Preventative intervention - behavioural risk modification

40

4%

Preventative Intervention - nutrition and chemoprevention

10

1%

Preventative Intervention - physical/biological risk modification

5

1%

Products with applications outside of medicine

4

0%

Support tool - for fundamental research

83

9%

Support tool - for medical intervention

44

5%

Therapeutic intervention - cellular and gene therapies

52

6%

Therapeutic intervention - complementary

4

0%

Therapeutic intervention - drug

249

28%

Therapeutic intervention - medical devices

19

2%

Therapeutic intervention - physical

9

1%

Therapeutic intervention - psychological/behavioural

57

6%

Therapeutic intervention - radiotherapy

7

1%

Therapeutic intervention - surgery

17

2%

Therapeutic intervention - vaccines

39

4%

Total

903

100%

Figure 1: Breakdown of products and interventions by type

Figure 1: Breakdown of products and interventions by type

Products and interventions by development stage

Table 2: Products and interventions by development stage

Stage of development

Number of instances

Percentage of total

Initial development

277

31%

Refinement, non-clinical

113

13%

Refinement, clinical

82

9%

Early clinical assessment

180

20%

Late clinical evaluation

107

12%

Market authorisation

18

2%

Small-scale adoption

71

8%

Wide-scale adoption

54

6%

Total

902

100%

 

Figure 2: Products and interventions by development stage

Figure 2: Products and interventions by development stage